Aim: To investigate the PK/PD relationship between unbound evolocumab, unbound PCSK9, and LDL-C following evolocumab administration, and the impact of target-mediated drug disposition (TMDD) on dose and regimen.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Atherosclerosis
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2015 Published by Elsevier Inc.